Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytosorbents Cor (NQ: CTSO )

1.880 +0.020 (+1.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 41,932
Open 1.920
Bid (Size) 1.840 (4)
Ask (Size) 1.880 (6)
Prev. Close 1.860
Today's Range 1.820 - 1.990
52wk Range 1.030 - 4.590
Shares Outstanding 44,362,386
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
From CytoSorbents
Via GlobeNewswire

Performance

YTD
+3.30%
+3.30%
1 Month
-25.69%
-25.69%
3 Month
-47.63%
-47.63%
6 Month
-44.21%
-44.21%
1 Year
+42.42%
+42.42%

More News

Read More
A Preview Of CytoSorbents's Earnings
Via Benzinga
Looking Into CytoSorbents's Return On Capital Employed
Via Benzinga
CytoSorbents Earnings Preview
Via Benzinga
CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation
From CytoSorbents
Via GlobeNewswire
Brady, America's Car-Mart And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico
From CytoSorbents
Via GlobeNewswire
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
From CytoSorbents
Via GlobeNewswire
CytoSorbents Reports Second Quarter 2023 Financial and Operational Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Report Second Quarter 2023 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents Appoints Alexander D’Amico as Chief Financial Officer
From CytoSorbents
Via GlobeNewswire
CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease
From CytoSorbents
Via GlobeNewswire
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
From CytoSorbents
Via GlobeNewswire
CytoSorbents This Week to Host its Virtual Annual Stockholders Meeting and to Present at the Jefferies Healthcare Conference
From CytoSorbents
Via GlobeNewswire
CytoSorbents Reports First Quarter 2023 Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Report First Quarter 2023 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents’ Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces Board Chairman Al W. Kraus To Retire
From CytoSorbents
Via GlobeNewswire
Landmark Publication Underscores Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation
From CytoSorbents
Via GlobeNewswire
CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)
From CytoSorbents
Via GlobeNewswire
CytoSorbents Comments on Bank Exposure and Diversified Cash Position
From CytoSorbents
Via GlobeNewswire
CytoSorbents Reports Fourth Quarter and Full Year 2022 Results
From CytoSorbents
Via GlobeNewswire
New European “Guidelines for the Management of Severe Perioperative Bleeding” Consider Hemoadsorption for the First-Time
From CytoSorbents
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.